Abstract
摘要
相似文献
1
FDA panel backs HIV drug.
AIDS Read. 2007 Jun;17(6):294.
2
FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
AIDS Alert. 2007 Sep;22(9):103.
3
FDA advisory committee approves Selzentry.
AIDS Patient Care STDS. 2009 Nov;23(11):987.
4
Something new under the sun. Maraviroc poised for approval.
GMHC Treat Issues. 2006 Aug-Dec;20(8-12):1-4.
5
FDA approves maraviroc tablets.
AIDS Patient Care STDS. 2007 Sep;21(9):702. doi: 10.1089/apc.2007.9970.
6
Maraviroc--new HIV drug. Emerging options need to be used wisely.
Posit Aware. 2007 Jul-Aug;18(4):18-9.
7
[CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
MMW Fortschr Med. 2011 May 5;153(18):30-1.
8
FDA approval: maraviroc.
AIDS Clin Care. 2007 Sep;19(9):75.
9
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
J Clin Pharm Ther. 2010 Dec;35(6):657-63. doi: 10.1111/j.1365-2710.2009.01148.x.
10
Two new drugs for HIV infection.
Med Lett Drugs Ther. 2008 Jan 14;50(1277):2-4.
Zotero 插件